Aortitis after switching short-acting granulocyte colony-stimulating factors in a lymphoma patient with HLA-B52.
Int J Hematol
; 119(5): 608-612, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38521841
ABSTRACT
Aortitis is a rare adverse event of granulocyte colony-stimulating factor (G-CSF) treatment. Several previous studies have described recurrent aortitis caused by re-administration of the same G-CSF. However, no previous studies have examined the safety of switching between short-acting G-CSFs in patients who develop aortitis. We report the case of a 55-year-old man with refractory diffuse large B-cell lymphoma, who developed G-CSF-associated aortitis. The aortitis was triggered by filgrastim and recurred after treatment with lenograstim. The patient possessed human leukocyte antigen B52, which has been implicated in Takayasu arteritis. In addition, a drug-induced lymphocyte stimulation test for lenograstim performed upon detection of recurrent G-CSF-associated aortitis produced a positive result. Our case suggests that switching from one short-acting G-CSF to another does not prevent recurrence of G-CSF-associated aortitis. Although the etiology of G-CSF-associated aortitis has not been fully elucidated, our case also suggests that some patients may be genetically predisposed to aortitis.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Aortitis
/
Granulocyte Colony-Stimulating Factor
/
Lymphoma, Large B-Cell, Diffuse
/
HLA-B52 Antigen
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Int J Hematol
Journal subject:
HEMATOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Japan